2009
DOI: 10.1177/0961203308095001
|View full text |Cite
|
Sign up to set email alerts
|

Clinical, biological and ultrasonographic remission in a patient with musculoskeletal systemic lupus erythematosus with rituximab

Abstract: Systemic lupus erythematosus (SLE) is a multiorganic autoimmune disease that affects skin, osteoarticular and kidney frequently. Rituximab showed efficacy in treatment of osteoarticular and haematological SLE, but its use has been generalised for renal disease. In our case, we showed efficacy of rituximab in SLE articular disease, showing an ultrasonographic improvement.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0
1

Year Published

2009
2009
2013
2013

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 14 publications
0
2
0
1
Order By: Relevance
“…SLEDAI-2K and ECLAM lack the sensitivity to identify local disease inflammation activity at the joint level because the presence of joint disease without signs of systemic or major organ involvement is not systematically analysed in these composite indices. Additional applications of musculoskeletal US to SLE patients have been recently developed, using this imaging technique in paediatric patients and to monitor biologic therapy [46,47].…”
Section: Discussionmentioning
confidence: 99%
“…SLEDAI-2K and ECLAM lack the sensitivity to identify local disease inflammation activity at the joint level because the presence of joint disease without signs of systemic or major organ involvement is not systematically analysed in these composite indices. Additional applications of musculoskeletal US to SLE patients have been recently developed, using this imaging technique in paediatric patients and to monitor biologic therapy [46,47].…”
Section: Discussionmentioning
confidence: 99%
“…Observa-se também uma grande preocupação em relação à segurança do procedimento, e em vários deles a abordagem é do TCTH versus altas doses de imunossupressão, com o emprego de anticorpos monoclonais com a finalidade de se obter a depleção de células T. 36,37,38 Tumores sólidos O TCTH nos tumores sólidos permanece controverso e discutível. Desde o inicio da década de 90, inúmeros ensaios clínicos foram propostos, principalmente os dirigidos para o tratamento do carcinoma metastático ou inflamatório de mama.…”
Section: Doenças Autoimunesunclassified
“…Synovitis and tenosynovitis in the upper and lower extremities have been defined in juvenile patients with SLE (39). US has been also used to define improvement in synovitis in patients undergoing treatment (40).…”
Section: Other Rheumatic Disordersmentioning
confidence: 99%